Silexion shares surge 17.02% intraday after positive preclinical data and Phase 2/3 trial plans for 2026.

Silexion Therapeutics surged 17.02% intraday after releasing a CEO letter highlighting significant preclinical results for SIL204, including over 90% tumor inhibition across pancreatic, colorectal, and lung cancer models, and outlining plans for a Phase 2/3 trial in locally advanced pancreatic cancer (LAPC) in H1 2026. The company confirmed positive regulatory feedback from Germany’s BfArM, completed non-toxicology studies, and secured $18 million in funding, positioning SIL204 to target a $30+ billion KRAS-driven cancer market. The announcement emphasized the asset’s potential to address unmet needs in metastatic disease and its dual-route strategy for combined intratumoral and systemic administration, reinforcing investor optimism about clinical validation and market potential in 2026.